^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    19(T2)28z1xx TRAC T cell

    i
    Other names: 19(T2)28z1xx TRAC T cell, 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells
    Associations

    News

    Trials
    Company:
    Memorial Sloan-Kettering Cancer Center, Takeda
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    21d
    Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    19(T2)28z1xx TRAC T cell
    1year
    Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    19(T2)28z1xx TRAC T cell
    over1year
    Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People with B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    19(T2)28z1xx TRAC T cell
    3years
    Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=30, Recruiting, Memorial Sloan Kettering Cancer Center
    New P1 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    19(T2)28z1xx TRAC T cell